Our analysis shows frequent mutations of IDH1 and IDH2 in the TCGA LGG (lower grade glioma) cohort and frequent amplifications of IDH1 in LIHC (liver hepatocellular carcinoma), as well as less frequent mutations and amplifications of IDH1 in CHOL, GBM, PRAD and SKCM. Here, IDH2 is linked to central nervous system cancer.